疫苗概念午后拉升！疫苗ETF富国（159645）盘中涨幅达3.87%

Core Viewpoint - The vaccine sector is experiencing a significant surge, driven by recent developments in vaccine approvals and the increasing demand for vaccination due to an aging population in China [1]. Group 1: Market Performance - The vaccine ETF, 富国 (159645), rose by 3.87% during the trading session, with notable increases in constituent stocks such as 华兰疫苗, which surged by 20%, 万孚生物, which increased by over 17%, and 智飞生物, which rose by over 13% [1]. Group 2: Company Developments - 华兰疫苗 announced that its shingles vaccine has received approval from the National Medical Products Administration for clinical trials, marking a significant breakthrough in its pipeline for important preventive measures [1]. Group 3: Industry Outlook - Long-term projections indicate a substantial growth potential for shingles vaccine demand, driven by the accelerating aging process in the domestic population and increasing vaccine penetration rates [1]. - The acceleration of approval processes for innovative vaccines and increased investment in vaccine research and development, supported by government policies, is expected to foster rapid growth in China's vaccine industry [1]. - The international expansion of vaccine markets, highlighted by recent outbreaks such as the Nipah virus in West Bengal, India, is also broadening the demand landscape for the vaccine industry [1]. Group 4: Investment Opportunities - The vaccine ETF 富国 (159645) closely tracks the 国证疫苗与生物科技指数 (980015), which comprises 50 A-share listed companies involved in the biotechnology sector, reflecting the overall performance of quality listed companies in the vaccine and biotechnology industries [1].